Longboard Pharmaceuticals Says Potential Dravet Syndrome Treatment Gets Rare Pediatric Disease, Orphan Drug Designations From FDA

MT Newswires Live09-19

Longboard Pharmaceuticals (LBPH) said Thursday its investigational drug bexicaserin for the treatment of Dravet syndrome has received Rare Pediatric Disease and Orphan Drug designations from the US Food and Drug Administration.

The Orphan Drug designation provides further regulatory support as the company progresses the development of bexicaserin, said Longboard Chief Medical Officer Randall Kaye.

The Rare Pediatric Disease designation provides the company with an opportunity to get a Priority Review Voucher that can be used for priority review of another Longboard compound or monetized, Kaye said.

Longboard shares were up 4% in premarket activity.

Price: 30.52, Change: +1.21, Percent Change: +4.13

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2468574999?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-19 21:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2468574999","market":"sg","top_or_hot":-1,"title":"Longboard Pharmaceuticals Says Potential Dravet Syndrome Treatment Gets Rare Pediatric Disease, Orphan Drug Designations From FDA","media":"MT Newswires Live","content":"<html><body><p> Longboard Pharmaceuticals (LBPH) said Thursday its investigational drug bexicaserin for the treatment of Dravet syndrome has received Rare Pediatric Disease and Orphan Drug designations from the US Food and Drug Administration.</p><p>The Orphan Drug designation provides further regulatory support as the company progresses the development of bexicaserin, said Longboard Chief Medical Officer Randall Kaye.</p><p>The Rare Pediatric Disease designation provides the company with an opportunity to get a Priority Review Voucher that can be used for priority review of another Longboard compound or monetized, Kaye said.</p><p>Longboard shares were up 4% in premarket activity.</p><p>Price: 30.52, Change: +1.21, Percent Change: +4.13</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Longboard Pharmaceuticals Says Potential Dravet Syndrome Treatment Gets Rare Pediatric Disease, Orphan Drug Designations From FDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongboard Pharmaceuticals Says Potential Dravet Syndrome Treatment Gets Rare Pediatric Disease, Orphan Drug Designations From FDA\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-19 21:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Longboard Pharmaceuticals (LBPH) said Thursday its investigational drug bexicaserin for the treatment of Dravet syndrome has received Rare Pediatric Disease and Orphan Drug designations from the US ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2468574999","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2468574999","pubTimestamp":1726751729,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Longboard Pharmaceuticals  said Thursday its investigational drug bexicaserin for the treatment of Dravet syndrome has received Rare Pediatric Disease and Orphan Drug designations from the US Food and Drug Administration.The Orphan Drug designation provides further regulatory support as the company progresses the development of bexicaserin, said Longboard Chief Medical Officer Randall Kaye.The Rare Pediatric Disease designation provides the company with an opportunity to get a Priority Review Voucher that can be used for priority review of another Longboard compound or monetized, Kaye said.Longboard shares were up 4% in premarket activity.Price: 30.52, Change: +1.21, Percent Change: +4.13","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LBPH":"Longboard Pharmaceuticals, Inc."},"translate_title":"Longboard Pharmaceuticals表示，潜在的Dravet综合征治疗方法获得FDA罕见儿科疾病孤儿药称号","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LBPH":1},"content_text":"Longboard Pharmaceuticals (LBPH) said Thursday its investigational drug bexicaserin for the treatment of Dravet syndrome has received Rare Pediatric Disease and Orphan Drug designations from the US Food and Drug Administration.The Orphan Drug designation provides further regulatory support as the company progresses the development of bexicaserin, said Longboard Chief Medical Officer Randall Kaye.The Rare Pediatric Disease designation provides the company with an opportunity to get a Priority Review Voucher that can be used for priority review of another Longboard compound or monetized, Kaye said.Longboard shares were up 4% in premarket activity.Price: 30.52, Change: +1.21, Percent Change: +4.13","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2468574999"}